St Jude hits stented heart valve milestone:
This article was originally published in Clinica
St Jude Medical says its has reached a significant milestone in its efforts to enter the US stented tissue heart valve market, after its Epic valve was implanted in the first patient of an FDA-approved clinical trial. The device, a porcine-based product, features the St Paul, Minnesota firm's proprietary Linx anti-calcification technology, designed to alleviate the calcification problems sometimes associated with tissue valves. Stented tissue valves represent around 45% of the current US heart valve market, says St Jude, which already markets the device, and another stented heart valve, called Biocor, outside the US.